Calithera Biosciences, Inc. (CALA) EPS Estimated At $-0.24

February 23, 2018 - By sdfsdfsdf

 Calithera Biosciences, Inc. (CALA) EPS Estimated At $ 0.24
Investors sentiment decreased to 1.22 in Q3 2017. Its down 2.03, from 3.25 in 2017Q2. It turned negative, as 16 investors sold Calithera Biosciences, Inc. shares while 21 reduced holdings. 14 funds opened positions while 31 raised stakes. 25.24 million shares or 49.47% less from 49.95 million shares in 2017Q2 were reported.
13,800 were accumulated by Balyasny Asset Management Limited Company. Adage Ptnrs Gp Limited Liability Corp reported 0.13% stake. 184,310 are owned by Panagora Asset Mngmt. California State Teachers Retirement reported 49,007 shares stake. Royal Bank & Trust Of Canada invested in 0% or 3,159 shares. Citadel Advsr Ltd Liability Corp has 0.01% invested in Calithera Biosciences, Inc. (NASDAQ:CALA). Strs Ohio invested in 3,600 shares or 0% of the stock. Pnc Financial Service accumulated 1,000 shares. Raymond James Financial Serv reported 17,000 shares. Ameritas Investment Partners invested in 2,688 shares or 0% of the stock. Bridgeway Capital reported 68,050 shares or 0.01% of all its holdings. The Georgia-based Invesco Limited has invested 0% in Calithera Biosciences, Inc. (NASDAQ:CALA). Franklin Street Advisors Incorporated Nc reported 35,580 shares. Millennium Management Limited Liability Corp, New York-based fund reported 482,136 shares. Acadian Asset Mgmt Ltd Limited Liability Company reported 0% of its portfolio in Calithera Biosciences, Inc. (NASDAQ:CALA).

Analysts expect Calithera Biosciences, Inc. (NASDAQ:CALA) to report $-0.24 EPS on March, 15.They anticipate $0.21 EPS change or 46.67 % from last quarter’s $-0.45 EPS. After having $-0.17 EPS previously, Calithera Biosciences, Inc.’s analysts see 41.18 % EPS growth. The stock decreased 0.62% or $0.05 during the last trading session, reaching $8.05. About 378,292 shares traded. Calithera Biosciences, Inc. (NASDAQ:CALA) has risen 278.82% since February 23, 2017 and is uptrending. It has outperformed by 262.12% the S&P500.

Calithera Biosciences, Inc. (NASDAQ:CALA) Ratings Coverage

Among 5 analysts covering Calithera Biosciences (NASDAQ:CALA), 5 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Calithera Biosciences had 10 analyst reports since July 24, 2015 according to SRatingsIntel. The firm earned “Market Outperform” rating on Wednesday, March 9 by JMP Securities. On Tuesday, October 25 the stock rating was initiated by Citigroup with “Sell”. The rating was maintained by H.C. Wainwright with “Buy” on Tuesday, March 28. The firm earned “Buy” rating on Monday, June 12 by H.C. Wainwright. The rating was initiated by Citigroup with “Buy” on Friday, July 24. H.C. Wainwright initiated the stock with “Buy” rating in Thursday, January 5 report. The rating was upgraded by Citigroup on Friday, February 16 to “Buy”. On Tuesday, January 24 the stock rating was upgraded by Citigroup to “Neutral”.

Calithera Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer in the United States. The company has market cap of $285.59 million. The Company’s lead product candidate is CB-839, an inhibitor of glutaminase, which is in Phase Ib/2 clinical trials for the treatment of solid tumors. It currently has negative earnings. The firm has a license agreement with Mars, Inc. to develop and commercialize Symbioscience's portfolio of arginase inhibitors for use in human healthcare; and license and research agreement with High Point Pharmaceuticals, LLC and TransTech Pharma LLC to develop and commercialize hexokinase II inhibitors.

Another recent and important Calithera Biosciences, Inc. (NASDAQ:CALA) news was published by which published an article titled: “Here’s Why Calithera Biosciences, Inc. Rose as Much as 25.2% Today” on February 16, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.